"Innovent and ASK Pharm to commercialise limertinib for lung cancer" was originally created and published by Pharmaceutical ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

We have gone through three generations of these TKIs. In the first generation were molecules like Erlotinib (Tarceva) and Gefitinib (Iressa), which were able to demonstrate high progression-free ...

In a multi-center, randomized, double-blind, controlled Phase 3 clinical trial, limertinib's efficacy and safety were compared with gefitinib in the first-line treatment of patients with locally ...

Notable examples include imatinib for treating chronic myelogenous leukemia and gastrointestinal tumors, gefitinib and erlotinib for non-small-cell lung cancers, trastuzumab in women with breast ...

The company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab) ...

AstraZeneca’s TAGRISSO® (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung ...

NICE said there is clinical trial evidence showing that Tagrisso stalls cancer growth longer than treatment with two older EGFR drugs, Roche’s Tarceva (erlotinib) and AZ’s Iressa (gefitinib).

Professor Russell Petty is a graduate of University of Dundee School of Medicine and he completed his initial general medical training in Dundee, Newcastle, and Hobart , then specialist and academic ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...